398 related articles for article (PubMed ID: 18707782)
1. The effect of amifostine or IMRT to preserve the parotid function after radiotherapy of the head and neck region measured by quantitative salivary gland scintigraphy.
Rudat V; Münter M; Rades D; Grötz KA; Bajrovic A; Haberkorn U; Brenner W; Debus J
Radiother Oncol; 2008 Oct; 89(1):71-80. PubMed ID: 18707782
[TBL] [Abstract][Full Text] [Related]
2. Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without Amifostine.
Münter MW; Hoffner S; Hof H; Herfarth KK; Haberkorn U; Rudat V; Huber P; Debus J; Karger CP
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):651-9. PubMed ID: 17175118
[TBL] [Abstract][Full Text] [Related]
3. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
Rosenthal DI; Chambers MS; Weber RS; Eisbruch A
Semin Oncol; 2004 Dec; 31(6 Suppl 18):25-8. PubMed ID: 15726519
[TBL] [Abstract][Full Text] [Related]
4. In regard to Münter et Al. Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without amifostine. (Int j radiat oncol biol phys 2007;67:651-659).
Messerschmidt GL; Oleka N
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1651-2; author reply 1652. PubMed ID: 18035221
[No Abstract] [Full Text] [Related]
5. Evaluation of salivary gland function after treatment of head-and-neck tumors with intensity-modulated radiotherapy by quantitative pertechnetate scintigraphy.
Münter MW; Karger CP; Hoffner SG; Hof H; Thilmann C; Rudat V; Nill S; Wannenmacher M; Debus J
Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):175-84. PubMed ID: 14697436
[TBL] [Abstract][Full Text] [Related]
6. Large cohort dose-volume response analysis of parotid gland function after radiotherapy: intensity-modulated versus conventional radiotherapy.
Dijkema T; Terhaard CH; Roesink JM; Braam PM; van Gils CH; Moerland MA; Raaijmakers CP
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):1101-9. PubMed ID: 18472355
[TBL] [Abstract][Full Text] [Related]
7. Scintigraphic assessment of salivary function after intensity-modulated radiotherapy for head and neck cancer: correlations with parotid dose and quality of life.
Chen WC; Lai CH; Lee TF; Hung CH; Liu KC; Tsai MF; Wang WH; Chen H; Fang FM; Chen MF
Oral Oncol; 2013 Jan; 49(1):42-8. PubMed ID: 22854066
[TBL] [Abstract][Full Text] [Related]
8. Protection of salivary function by intensity-modulated radiation therapy in patients with head and neck cancer.
Chao KS
Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):20-5. PubMed ID: 11917280
[TBL] [Abstract][Full Text] [Related]
9. Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer.
Thorstad WL; Chao KS; Haughey B
Semin Oncol; 2004 Dec; 31(6 Suppl 18):8-12. PubMed ID: 15726516
[TBL] [Abstract][Full Text] [Related]
10. In regards to Münter et Al. (Int J Radiat Oncol Biol Phys 2007;67:651-659).
Samuels MA
Int J Radiat Oncol Biol Phys; 2007 Sep; 69(1):318; author reply 318-9. PubMed ID: 17707287
[No Abstract] [Full Text] [Related]
11. Preservation of parotid function with uncomplicated conformal radiotherapy.
Maes A; Weltens C; Flamen P; Lambin P; Bogaerts R; Liu X; Baetens J; Hermans R; Van den Bogaert W
Radiother Oncol; 2002 May; 63(2):203-11. PubMed ID: 12063010
[TBL] [Abstract][Full Text] [Related]
12. Impact of salivary gland dosimetry on post-IMRT recovery of saliva output and xerostomia grade for head-and-neck cancer patients treated with or without contralateral submandibular gland sparing: a longitudinal study.
Wang ZH; Yan C; Zhang ZY; Zhang CP; Hu HS; Tu WY; Kirwan J; Mendenhall WM
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1479-87. PubMed ID: 20934262
[TBL] [Abstract][Full Text] [Related]
13. Parotid-sparing intensity-modulated radiotherapy (IMRT) for nasopharyngeal carcinoma: preserved parotid function after IMRT on quantitative salivary scintigraphy, and comparison with historical data after conventional radiotherapy.
Hsiung CY; Ting HM; Huang HY; Lee CH; Huang EY; Hsu HC
Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):454-61. PubMed ID: 16839707
[TBL] [Abstract][Full Text] [Related]
14. [Quantitative and qualitative investigations of salivary gland function in dependence on irradiation dose and volume for reduction of xerostomia in patients with head-and-neck cancer].
Kuhnt T; Jirsak N; Müller AC; Pelz T; Gernhardt C; Schaller HG; Janich M; Gerlach R; Dunst J
Strahlenther Onkol; 2005 Aug; 181(8):520-8. PubMed ID: 16044220
[TBL] [Abstract][Full Text] [Related]
15. Comparison of xerostomia incidence after three-dimensional conformal radiation therapy and contralateral superficial lobe parotid-sparing intensity-modulated radiotherapy for oropharyngeal and hypopharyngeal cancer.
Kawamoto T; Nihei K; Nakajima Y; Kito S; Sasai K; Karasawa K
Auris Nasus Larynx; 2018 Oct; 45(5):1073-1079. PubMed ID: 29397249
[TBL] [Abstract][Full Text] [Related]
16. Can dose reduction to one parotid gland prevent xerostomia?--A feasibility study for locally advanced head and neck cancer patients treated with intensity-modulated radiotherapy.
Anand AK; Jain J; Negi PS; Chaudhoory AR; Sinha SN; Choudhury PS; Kumar R; Munjal RK
Clin Oncol (R Coll Radiol); 2006 Aug; 18(6):497-504. PubMed ID: 16909975
[TBL] [Abstract][Full Text] [Related]
17. Dose-response relationships within the parotid gland after radiotherapy for head and neck cancer.
Bussels B; Maes A; Flamen P; Lambin P; Erven K; Hermans R; Nuyts S; Weltens C; Cecere S; Lesaffre E; Van den Bogaert W
Radiother Oncol; 2004 Dec; 73(3):297-306. PubMed ID: 15588874
[TBL] [Abstract][Full Text] [Related]
18. Radiation-induced volume changes in parotid and submandibular glands in patients with head and neck cancer receiving postoperative radiotherapy: a longitudinal study.
Wang ZH; Yan C; Zhang ZY; Zhang CP; Hu HS; Kirwan J; Mendenhall WM
Laryngoscope; 2009 Oct; 119(10):1966-74. PubMed ID: 19688858
[TBL] [Abstract][Full Text] [Related]
19. Prospective longitudinal assessment of parotid gland function using dynamic quantitative pertechnate scintigraphy and estimation of dose-response relationship of parotid-sparing radiotherapy in head-neck cancers.
Gupta T; Hotwani C; Kannan S; Master Z; Rangarajan V; Murthy V; Budrukkar A; Ghosh-Laskar S; Agarwal JP
Radiat Oncol; 2015 Mar; 10():67. PubMed ID: 25889705
[TBL] [Abstract][Full Text] [Related]
20. Dose-volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy.
Blanco AI; Chao KS; El Naqa I; Franklin GE; Zakarian K; Vicic M; Deasy JO
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1055-69. PubMed ID: 15990009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
